SMAD5 and lymphoma: Since the overexpression of miR-155 by targeting SMAD5 makes DBLCL cells resistant to the growth-inhibitory effects of both TGF-beta1 and BMP, SMAD5 may represent a unique mechanism used by lymphoma cells to escape the tumor suppressive effects of the TGF-beta family [65].